AxoGen, Inc. (NASDAQ:AXGN) Short Interest Update

AxoGen, Inc. (NASDAQ:AXGN - Get Free Report) was the recipient of a significant increase in short interest during the month of January. As of January 31st, there was short interest totalling 1,870,000 shares, an increase of 50.8% from the January 15th total of 1,240,000 shares. Based on an average daily trading volume, of 416,600 shares, the days-to-cover ratio is presently 4.5 days.

AxoGen Trading Down 0.1 %

AxoGen stock traded down $0.01 during midday trading on Monday, reaching $18.13. The stock had a trading volume of 318,705 shares, compared to its average volume of 489,302. AxoGen has a twelve month low of $5.55 and a twelve month high of $19.18. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.74 and a quick ratio of 2.47. The firm has a market cap of $797.90 million, a price-to-earnings ratio of -56.66 and a beta of 1.00. The firm's fifty day simple moving average is $16.92 and its two-hundred day simple moving average is $14.45.

Analysts Set New Price Targets

Separately, Canaccord Genuity Group boosted their target price on AxoGen from $18.00 to $22.00 and gave the stock a "buy" rating in a research report on Monday, February 3rd.

Institutional Investors Weigh In On AxoGen

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AXGN. Quest Partners LLC increased its stake in AxoGen by 23,066.7% in the third quarter. Quest Partners LLC now owns 2,085 shares of the medical equipment provider's stock valued at $29,000 after acquiring an additional 2,076 shares during the period. R Squared Ltd bought a new position in shares of AxoGen during the 4th quarter worth approximately $30,000. US Bancorp DE acquired a new stake in AxoGen in the 4th quarter valued at $30,000. nVerses Capital LLC acquired a new position in AxoGen during the third quarter worth $56,000. Finally, Harvest Fund Management Co. Ltd bought a new position in shares of AxoGen during the fourth quarter valued at $93,000. Hedge funds and other institutional investors own 80.29% of the company's stock.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.